Summary
Despite expressing both Fas and Fas ligand, DU145 and LNCaP prostate cancer cells were resistant to anti-Fas-induced cell death. Resistance to Fas-mediated cytotoxicity could be overcome in DU145, but not in LNCaP, cells by pretreating cells with sublethal doses of cytotoxic drugs, such as camptothecin. Activated caspases were shown to be required for this cytotoxicity. Indeed, poly(ADP-Ribose) polymerase was shown to be proteolytically cleaved in cells treated with camptothecin plus anti-Fas, but not in cells treated with anti-Fas only. Moreover, pretreatment of cells with ZVAD completely blocked camptothecin-mediated Fas-induced apoptosis. Sensitization of cells to Fas-induced cell death did not involve up-regulation of Fas or FasL, and it was independent of alterations in the cell cycle. Reactive oxygen intermediates (ROI) have been shown to be important mediators of drug-induced apoptosis. Here, we demonstrate that treatment of DU145 cells with camptothecin, anti-Fas, or both, did not alter the intracellular levels of peroxide or superoxide anion.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Buttke, T. M. & Sandstrom, P. A. (1994). Oxidative stress as a mediator of apoptosis. Immunol Today 15: 7–10.
Carter, H. B. & Coffey, D. S. (1990). The prostate: an increasing medical problem. Prostate 16: 187–197.
Chung, L. W. K. (1995). The role of stromal-epithelial interaction in normal and malignant growth. Cancer Surv 23: 33–42.
Clément, M-V & Stamenkovic, I. (1996). Superoxide anion is a natural inhibitor of Fas-mediated cell death. EMBO J 15: 216–225.
Costa-Pereira, A. P. & Cotter, T. G. (1999). Metabolic alterations associated with apoptosis. In Apoptosis – a Practical Approach, Studinzski G (ed). Oxford University Press: Oxford
Denmeade, S. R., Lin, X. S. & Isaacs, J. T. (1996). Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28: 251–265.
Dobbelsteen, DJ van den, Nobel, C. S. I., Schlegel, J., Cotgreave, I. A., Orrenius, S. & Slater, A. F. G. (1996). Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-Fas/APO-1 antibody. J Biol Chem 271: 15420–15427.
Eischen, C. M., Kottke, T. J., Martins, L. M., Basi, G. S., Tung, J. S., Earnshaw, W. C., Leibson, P. J. & Kaufmann, S. H. (1997). Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 90: 935–943.
Enari, M., Talanian, R. V., Wong, W. W. & Nagata, S. (1996). Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature (Lond) 380: 723–726.
Figueroa, J. A., Lee, A. V., Jackson, J. G. & Yee, D. (1995). Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop. J Clin Endocrinol Metab 80: 3476–3482.
Friesen, C., Herr, I., Krammer, P. H. & Debatin, K-M (1996). Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukaemia cells. Nature Med 2: 574–577.
Gorman, A. M., Samali, A., McGowan, A. J. & Cotter, T. G. (1997a). The use of flow cytometry techniques in studying mechanisms of apoptosis in leukemic cells. Cytometry 29: 97–105.
Gorman, A. M., McGowan, A. J. & Cotter, T. G. (1997b). Role of peroxide and superoxide anion during tumour cell apoptosis. FEBS 404: 27–33.
Green, D. R. (1997). A Myc-induced apoptosis pathway surfaces. Science 278: 1246–1247.
Herr, I., Wilhelm, D., Böhler, T., Angel, P. & Debatin, K-M (1997). Activation of CD95 (APO-1/Fas) signalling by ceramide mediates cancer therapy-induced apoptosis. EMBO J 16: 6200–6208.
Hsiang, Y. H., Likan, M. G. & Liu, L. F. (1989). Arrest of replication forks by drug stabilised topoisomerase-I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077–5082.
Huggins, C. & Hodges, C. V. (1941). Studies on prostate cancer. I. The effect of castration, of oestrogen, and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293–297.
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J-L, Schröter, M., Burns, K., Mattmann, C., Rimoldi, D., French, L. E. & Tschopp, J. (1997). Inhibition of death receptor signals by cellular FLIP. Nature (Lond) 388: 190–195.
Isaacs, W. B., Carter, B. S. & Ewing, C. M. (1991). Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51: 4716–4720.
Kasahara, Y., Iwai, K., Yachie, A., Ohta, K., Konno, A., Seki, H., Miyawaki, T. & Taniguchi, N. (1997). Involvement of reactive oxygen intermediates in spontaneous and CD95(Fas/APO-1)-mediated apoptosis of neutrophils. Blood 89: 1748–1753.
Kroemer, G. (1997). Mitochondrial implication in apoptosis. Towards an endosymbiont hypothesis of apoptosis in evolution. Cell Death Differ 4: 443–456.
Lennon, S. V., Martin, S. J. & Cotter, T. G. (1991). Dose-dependent induction of apoptosis in human tumour cell lines by widely diverse stimuli. Cell Prolif 24: 203–204.
Longthorne, V. L. & Williams, G. T. (1997). Caspase activity is required for commitment to Fas-mediated apoptosis. EMBO J 16: 3805–3812.
McGahon, A. J., Costa-Pereira, A. P., Daly, L. & Cotter, T. G. (1998). Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system. Br J Haematol 101: 539–547.
McGowan, A. J., Fernandes, R. S., Verhaegen, S. & Cotter, T. G. (1994). Zinc inhibits UV radiation-induced apoptosis but fails to prevent subsequent cell death. Int J Radiat Biol 66: 343–349.
McGowan, A. J., Ruiz-Ruiz, M. C., Gorman, A. M., Lopez-Rivas, A. & Cotter, T. G. (1996). Reactive oxygen intermediate(s) (ROI): common mediator(s) of poly(ADP-ribose polymerase (PARP) cleavage and apoptosis. FEBS 392: 299–303.
McGowan, A. J., Bowie, A. G., O’Neill, L. A. J. & Cotter, T. G. (1998). The production of a reactive oxygen intermediate (ROI) during the induction of apoptosis induced by cytotoxic agents. Exp Cell Res 238: 248–256.
Müller, M., Strand, S., Hug, H., Heinemann, E-M, Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H. & Galle, P. R. (1997). Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99: 404–413.
Nagata, S. (1997). Apoptosis by death factor. Cell 88: 355–365.
Oehm, A., Berhmann, I., Falk, W., Pawlita, M., Maier, G., Klas, G., Li-Weber, C. M., Richards, S., Dhein, J., Trauth, B. C., Ponsting, H. & Krammer, P. H. (1992). Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumour necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 267: 10709–10715.
Owen-Shaub, L. B., Radinsky, R., Kruzel, E., Berry, K. & Yonehara, S. (1994). Anti-Fas on non-hematopoietic tumours: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 54: 1580–1586.
Rokhlin, O. W., Bishop, G. A., Hostager, B. S., Waldschmidt, T. J., Sidorenko, S. P., Pavloff, N., Kiefer, M. C., Umanski, S. R., Glover, R. A. & Cohen, M. B. (1997). Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 57: 1758–1768.
Schulze-Osthoff, K., Krammer, P. & Droge, W. (1994). Divergent signalling via APO-1/Fas and the TNF receptor, two homologues molecules involved in physiological cell death. EMBO J 13: 4587–4596.
Villunger, A., Egle, A., Kos, M., Hartmann, B. L., Geley, S., Kofler, R. & Greil, R. (1997). Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signalling in human T-acute lymphatic leukemia cells. Cancer Res 57: 3331–3334.
Yagoda, A. & Petrylak, D. (1992). Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 70: 329–334.
Yonehara, S., Ishi, A. & Yonehara, M. (1989). A cell-killing monoclonal antibody (anti-Fas) to a surface antigen codownregulated with the receptor of tumour necrosis factor. J Exp Med 181: 1747–1756.
Widmann, C., Gibson, S. & Johnson, G. L. (1998). Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals. J Biol Chem 273: 7141–7147.
Wyllie, A. H., Kerr, J. F. R. & Currie, A. R. (1980). Cell death: the significance of apoptosis. Int Rev Cytol 68: 251–306.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Costa-Pereira, A., Cotter, T. Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis. Br J Cancer 80, 371–378 (1999). https://doi.org/10.1038/sj.bjc.6690365
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690365
Keywords
This article is cited by
-
In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cells
Scientific Reports (2019)
-
The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer
Cell Death & Disease (2014)
-
Defects in death-inducing signalling complex formation prevent JNK activation and Fas-mediated apoptosis in DU 145 prostate carcinoma cells
British Journal of Cancer (2003)
-
Anisomycin activates JNK and sensitises DU 145 prostate carcinoma cells to Fas mediated apoptosis
British Journal of Cancer (2002)